Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy

J Vasc Interv Radiol. 2007 Apr;18(4):553-61; quiz 562. doi: 10.1016/j.jvir.2007.02.002.

Abstract

Hepatic arterial therapy with yttrium-90 microspheres exploits the avenue provided by the neoplastic microvasculature to deliver high-energy, low-penetrating therapeutic doses of radiation. Variant hepatic arterial anatomy, collateral vessels, and changes in flow dynamics during treatment can affect particle dispersion and lead to nontarget particle distribution and subsequent gastrointestinal morbidity. Awareness of these variances and techniques to prevent gastrointestinal tract microsphere delivery is essential in mitigating this serious complication. Our aim is to increase the understanding of the role of various imaging and preventative techniques in minimizing this undesired effect.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / secondary
  • Adult
  • Aged
  • Brachytherapy / adverse effects*
  • Embolization, Therapeutic / adverse effects*
  • Gastrointestinal Tract / blood supply
  • Hepatic Artery*
  • Humans
  • Injections, Intra-Arterial
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary
  • Male
  • Microspheres
  • Peptic Ulcer / complications
  • Peptic Ulcer / etiology*
  • Peptic Ulcer / pathology
  • Peptic Ulcer Hemorrhage / etiology*
  • Peptic Ulcer Hemorrhage / pathology
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • Technetium Tc 99m Aggregated Albumin
  • Yttrium Radioisotopes / administration & dosage
  • Yttrium Radioisotopes / adverse effects*

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Aggregated Albumin
  • Yttrium Radioisotopes